2795-5001

S2795-50012024000100011

10.24875/pjdv.24000013

Portugal

30 03 2024

82 1 11 22

2021 184

226-36

2021 76

59-70

2020 125

380-7

2004 59

869-73

2011 66

317-30

2016 175

1153-65

2018 18

425-48

2022 77

734-66

2022 150

1403-4

2022 149

1819-31

2013 68

27-36

2019 74

2427-36

2022 8

2019 11

29-42

2020 200

242-9

2020 75

3208-15

2018 282

232-47

2022 22

294-308

2023 78

389-401

2021 10

2906

2022 149

1221-2

2020 145

1510-6

2020 8

318-25.e5

2021 147

2295-304.e12

2014 69

683-91

2008 63

176-80

2011 41

1386-91

2017 13

2018 73

940-8

2010 65

459-66

1989 36

617-9

2014 133

1270-7

2020 80

1617-34

2017 72

519-33

2017 17

375-85

2020 27

e455-67

2019 155

29-38

2016 71

1135-44

2017 31

1715-21

2014 150

288-90

2020 59

38-45

2018 179

210-2

2018 177

360-4

2018 2018

5615109

2007 150

509-18

2018 6

1386-8.e1

2010 65

1478-82

2018 6

586-99

2006 55

705-9

2012 2

2022 36

e645-6

2019 180

199-200

2020 124

2-12

2019 381

1321-32

2023 151

AB130

2022 132

2022 38

610-1

2022 10

2050313X221117702

2022 149

AB312

2021 9

1067-78

2020 50

799-804

2022 82

461-8

NUCALA®(Mepolizumab)

2021 92

2018 16

477-8

2018 32

e112-3

2020 383

1389-91

2019 180

91-102

2022 149

1683-90.e7

2023 78

1269-79

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023 2023

2021 147

456-69

2023 151

AB203

Escient Pharmaceuticals Announces Ind Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders 2023

2022 77

2355-66

2021 27

1961-9

2022 150

1498-506.e2